A Randomized, Multicenter Open Label Phase II Trial of Paclitaxel + Ramucirumab Versus Paclitaxel Alone in Patients With Squamous-cell Carcinoma of the Esophagus, Refractory or Intolerant to Combination Therapy With Fluoropyrimidine and Platinum-based Drugs - The RAMOS STUDY
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs Ramucirumab (Primary) ; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms RAMOS
- 04 Mar 2019 Status changed from not yet recruiting to recruiting.
- 15 Feb 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.
- 23 Aug 2018 New trial record